Abstract
Prazosin, a balanced vasodilator acting by blockade of postsynaptic alpha-1 adrenoreceptors, is used mainly for treatment of hypertension and congestive heart failure. Several investigators claimed that prazosin is effective also in coronary spasm. Long-term use of prazosin is associated with development of tolerance in a considerable portion of the patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ogasawara B, et al: Plasma renin activity and plasma concentrations of norepinephrine and cyclic nucleotides in heart failure after prazosin. Clin Pharmacol Ther 29:464, 1981.
Goldman SA, et al: Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure. Am J Med 68:36, 1980.
Packer M, et al: Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59:531, 1979.
Awan NA, et al: Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. Am Heart J 101:541, 1981.
Stein L, et al: Acute and chronic haemodynamic effects of prazosin in left ventricular failure. Br Heart J 45:186, 1981.
Colucci WS, et al: Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol 45:337, 1980.
Stokes GS, et al: Long-term use of prazosin in combination or alone for treating hypertension. Med J Aust [Spec Suppl]:13, 1977.
Lund-Johansen P: Hemodynamic changes at rest and during exercise in longterm prazosin therapy for essential hypertension. Postgrad Med J [Spec] 45:77, 1975.
Gould L, et al: Prazosin therapy in congestive heart failure [letter to the editor]. Am Heart J 104:1392, 1982.
Tzivoni D, et al: Prazosin therapy for refractory variant angina. Am Heart J 105:262, 1983.
Chierchia S, et al: α-Adrenergic receptors and coronary spasm: an elusive link. Circulation 69:8, 1984.
Robertson RM, et al: Alpha-adrenergic blockade in vasotonic angina: lack of efficacy of specific alpha1-receptor blockade with prazosin. J Am Coll Cardiol 2:1146, 1983.
Rygnestad TK, Dale O: Self-poisoning with prazosin. Acta Med Scand 213:157, 1983.
Rubin PC, Blachke TF: Studies on the clinical pharmacology of prazosin. 1. Cardiovascular, catecholamine and endocrine changes following a single dose. Br J Clin Pharmacol 10:23, 1980.
Taylor LA, et al: The metabolic fate of prazosin. Xenobiotica 7:357, 1973.
Althius TH, Hess HJ: Synthesis and identification of the major metabolites of prazosin formed in dog and rat. J Med Chem 20:146, 1977.
Rubin PC, et al: Prazosin disposition in young and elderly subjects. Br J Clin Pharmacol 12:401, 1981.
New Zeland Hypertension Study Group: Four to seven year follow up of patients on prazosin. NZ Med J 92:341, 1980.
Seideman P, et al: Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 13:865, 1982.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Schneeweiss, A., Schettler, G. (1987). Prazosin. In: Cardiovascular Drug Therapy in the Elderly. Developments in Cardiovascular Medicine, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2063-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2063-0_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9225-8
Online ISBN: 978-1-4613-2063-0
eBook Packages: Springer Book Archive